Trial Profile
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary)
- Indications Hyperparathyroidism; Parathyroid cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 05 Dec 2006 Status change
- 18 Aug 2005 New trial record.